{"id":"NCT01519089","sponsor":"Pfizer","briefTitle":"A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis","officialTitle":"A Phase 3, Multi Site, Randomized, Double Blind Study Of The Long-term Safety, Tolerability And Efficacy Of 2 Oral Doses Of Cp 690,550 In Subjects With Moderate To Severe Plaque Psoriasis And/or Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2012-01-26","resultsPosted":"2015-08-13","lastUpdate":"2015-08-13"},"enrollment":95,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690, 550","otherNames":[]}],"arms":[{"label":"CP-690,550 10 mg BID","type":"EXPERIMENTAL"},{"label":"CP690,550 5 mg BID","type":"EXPERIMENTAL"}],"summary":"The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis. This study will also to compare the efficacy of two oral doses of CP-690,550 (5 mg BID and 10 mg BID) after 16 weeks of treatment.","primaryOutcome":{"measure":"Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"CP-690,550 5 mg BID","deltaMin":62.8,"sd":null},{"arm":"CP-690,550 10 mg BID","deltaMin":72.7,"sd":null},{"arm":"Total","deltaMin":67.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":3},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921137&StudyName=A%20Long%20Term%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%20And%20Efficacy%20Of%20CP-690%2C550%20In%20Patients%20With%20Moderate%20To%20Severe%20Plaque%20Psori"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":47},"commonTop":["Nasopharyngitis","Herpes zoster","Tinea pedis","Psoriasis","Influenza"]}}